Alexander Sanchez/iStock via Getty Images
In its annual review of marijuana reform accomplishments, the Congressional Cannabis Coalition remarked that 2022 was a “historic year” as a marijuana research bill was signed into law this month and President Biden asked for a review of how marijuana is scheduled in October.
Looking ahead to 2023, coalition members said given these developments and other legislation introduced in both houses of Congress, “tremendous bipartisan momentum for cannabis reform sets the stage for a productive 2023 and 118th Congress.”
While the memo paints a rosy picture on cannabis reform efforts, many marijuana industry observers are ending the year unhappy as marijuana banking legislation, the SAFE Banking Act, got mired in the Senate, and cannabis legalization efforts went nowhere.
The coalition is co-chaired by Reps. Earl Blumenauer (D-Ore.), Dave Joyce (R-Ohio), Barbara Lee (D-Calif.) and Brian Mast (R-Fla.).
“Congress must catch up with the majority of Americans who support ending the failed and discriminatory federal prohibition,” said Rep. Blumenauer, Marijuana Moment reported. The memo mentioned a November Gallup poll that found 68% of Americans support marijuana legalization.
Multi-state operators: Trulieve Cannabis (OTCQX:TCNNF); Green Thumb Industries (OTCQX:GTBIF); Curaleaf Holdings (OTCPK:CURLF); MedMen Enterprises (OTCQB:MMNFF); Acreage Holdings (OTCQX:ACRHF); Ayr Wellness (OTCQX:AYRWF); Verano Holdings (OTCQX:VRNOF); and Jushi Holdings (OTCQX:JUSHF).
Cannabis ETFs: AdvisorShares Pure Cannabis ETF (YOLO), Amplify Seymour Cannabis ETF (CNBS), ETFMG Alternative Harvest ETF (NYSEARCA:MJ), AdvisorShares Pure US Cannabis ETF (MSOS), and Global X Cannabis ETF (POTX).
New York is slated to open its first adult-use marijuana dispensary on Thursday.
Image and article originally from seekingalpha.com. Read the original article here.